T
Tsontcho Ianchulev
Researcher at University of California, San Francisco
Publications - 45
Citations - 4253
Tsontcho Ianchulev is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Ranibizumab & Glaucoma. The author has an hindex of 25, co-authored 41 publications receiving 3916 citations. Previous affiliations of Tsontcho Ianchulev include Genentech & University of Southern California.
Papers
More filters
Journal ArticleDOI
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
TL;DR: A 2-year phase III trial designated ANCHOR as discussed by the authors compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV.
Journal ArticleDOI
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Carl D. Regillo,David M. Brown,Prema Abraham,Huibin Yue,Tsontcho Ianchulev,Susan Schneider,Naveed Shams +6 more
TL;DR: In this article, the authors evaluated the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Journal ArticleDOI
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
David S. Boyer,Jeffrey S. Heier,David M. Brown,Steven Francom,Tsontcho Ianchulev,Roman G. Rubio +5 more
TL;DR: Intravitreal ranibizumab was safe and well tolerated in a large population of subjects with neovascular AMD and had a beneficial effect on VA, and future investigations will seek to establish optimal dosing regimens for persons with nevascular AMD.
Anchor study group. ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the anchor study
TL;DR: In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV.
Journal ArticleDOI
Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts.
Steven D. Vold,Iqbal Ike K. Ahmed,E. Randy Craven,Cynthia Mattox,Robert L. Stamper,Mark Packer,Reay H. Brown,Tsontcho Ianchulev +7 more
TL;DR: This RCT demonstrated safe and sustained 2-year reduction in IOP and glaucoma medication use after microinterventional surgical treatment for mild-to-moderate POAG.